Posts

FDA Doubtful Over Benefit of Sarepta’s Duchenne Gene Th...

It is unclear if the first gene therapy for Duchenne muscular dystrophy will be ...

Synlogic’s SYNB1934 receives orphan drug status from US...

SYNB1934 has also received orphan drug designation from the European Medicines A...

China clears sNDA for combination therapy of NSCLC

Approval was given to TYVYT (sintilimab injection) plus bevacizumab and chemothe...

Amgen enlists TScan’s target discovery platform for Cro...

TScan will receive $30m upfront and a possible $500m in milestones to aid T cell...

Gilead wins patent battle with US government over HIV P...

A federal jury has ruled in favour of Gilead, stating that the government’s pate...

First-in-class migraine treatment Vydura approved for N...

The Scottish Medicines Consortium includes the first gepant for migraines on NHS...

Sobi agrees to buy CTI BioPharma for $1.7bn

The acquisition will strengthen Sobi's haematology medicines portfolio with the ...

Alvotech and Polifarma sign agreement to commercialise ...

The trial will assess the efficacy, safety and immunogenicity of the therapy com...

CytoMed and MD Anderson partner to use gdTc for cancer ...

The research teams will examine the use of CytoMed’s allogeneic gdTc on multiple...

Roche buys worldwide rights to Zion Pharma’s ZN-A-1041

ZN-A-1041 targets the human epidermal growth factor receptor 2 and is designed t...

Microparticle analysis: methods and uses in the pharmac...

Particle analysis on a micro-scale is a significant topic in several fields of a...

Why health care needs to shift its thinking on AI, FDA’...

In the latest edition of STAT's Health Tech newsletter: Why health care needs to...

Who’s in charge of the White House Covid response after...

The White House is in the middle of setting up a new pandemic response office, b...

STAT+: What FDA mandate? Sun Pharma halts shipments fro...

The FDA has found that a Sun Pharmaceuticals facility in India failed to comply ...

STAT+: Gilead defeats federal government in closely wat...

A U.S. court jury handed a major win to Gilead Sciences on Tuesday in a closely ...

Breast cancer screening should begin at 40, not 50, fed...

The new guidelines, which recommend all women begin screening mammography at age...